A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors

Cancer Biology & Therapy
Philip EliadesHensin Tsao

Abstract

Nearly 100% of melanomas have a defect in the p16(INK4A):cyclin D-CDK4/6:RB pathway, leading to abnormal cell cycle control and unregulated cellular proliferation. Here, we report that P1446A-05, a novel multi-CDK inhibitor has significant inhibitory activity against cutaneous and uveal melanoma. Mechanistic studies revealed that P1446A-05 inhibits phosphorylation targets of CDK members, and induces cell cycle arrest and apoptosis irrespective of melanoma genotype or phenotype. Additionally, we show preclinical evidence that P1446A-05 can synergize with other small molecule inhibitors previously studied in melanoma. Collectively, these data demonstrate that targeting cell cycle and transcriptional CDKs with a small molecule multi-CDK inhibitor is a viable approach for developing novel anti-melanoma therapeutics.

References

Mar 1, 1985·Molecular and Cellular Biology·R A PaduaG A Currie
Dec 1, 1996·Journal of Dermatological Science·Y KatagataS Kondo
Feb 21, 1998·Current Biology : CB·S M van HamJ Neefjes
Nov 16, 2001·Biochemical and Biophysical Research Communications·Y SaitoK Maruyama
Mar 21, 2002·Nature Reviews. Cancer·M Malumbres, M Barbacid
Oct 21, 2005·Trends in Biochemical Sciences·Marcos Malumbres, Mariano Barbacid
Nov 18, 2005·The New England Journal of Medicine·John A CurtinBoris C Bastian
Feb 25, 2009·Nature Reviews. Cancer·Marcos Malumbres, Mariano Barbacid
Oct 14, 2011·The Journal of Investigative Dermatology·Zhenyu JiHensin Tsao
Jul 3, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhenyu JiHensin Tsao
Jul 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Katherine L NathansonGeorgina V Long
Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen E Sheppard, Grant A McArthur
Jan 11, 2014·Pigment Cell & Melanoma Research·David M Miller, Keith T Flaherty
Dec 19, 2014·The Journal of Investigative Dermatology·Raj KumarHensin Tsao
Jan 15, 2015·Current Opinion in Oncology·Belinda LeeGrant McArthur

❮ Previous
Next ❯

Citations

Feb 28, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Pranav GuptaZhe-Sheng Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
flow cytometry

Clinical Trials Mentioned

NCT00840190
NCT00772876

Software Mentioned

GraphPad Prism
CompuSyn
FlowJo

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cell Cycle Pathways

Cell cycle is a complex process regulated by several signal transduction pathways and enzymes. Here is the latest research on regulation of cell cycle and cell cycle pathways.